
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharmaceuticals Inc. has demonstrated substantial growth potential, highlighted by a 10% quarter-over-quarter increase and a 5% year-over-year rise in top-line revenue for 3Q25, totaling $191.8 million, which surpassed market expectations. The company anticipates continued growth from key products such as Baqsimi and Primatene Mist, with projections of high-single digit unit growth in 2025 and a return to double-digit growth by 2026. Additionally, the firm remains optimistic about upcoming product approvals and launches, further solidifying its positive outlook within the biopharmaceutical market.
Bears say
Amphastar Pharmaceuticals Inc. is facing significant downward pressure on its revenue forecasts due to intensifying competition in key product categories, particularly iron sucrose and glucagon, with sales expectations for iron sucrose revised downward from $60 million annually to approximately $5 million quarterly. The emergence of additional competitors in the glucagon market has further compounded challenges, leading to projections that annual sales for this product will dip below $70 million starting in 2026. Furthermore, the anticipated return to double-digit top-line growth in 2026 has been tempered, with expectations now adjusted to high-single-digit to low-double-digit growth rates, thereby indicating a more cautious outlook for the company's financial performance moving forward.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares